October 09, 2019
Perrigo Company plc (NYSE; TASE: PRGO) announced that its “Quitting is Better” nicotine replacement therapy campaign has earned national recognition from the Consumer Healthcare Products Association (CHPA) Educational Foundation for innovation and strategic marketing in the consumer healthcare products industry.
October 08, 2019
Upon receiving communication from the U.S. Food and Drug Administration (FDA) regarding the potential for presence of N-nitrosodimethylamine (NDMA) in certain ranitidine-based products, Perrigo Company plc promptly initiated testing of its externally sourced ranitidine API and ranitidine-based products.
September 16, 2019
The Perrigo Charitable Foundation and Perrigo employees have joined together to help victims of Hurricane Dorian both within the U.S. and internationally. Hurricane Dorian impacted multiple southeast states, the Caribbean, and the Bahamas as it made landfall last week.
September 05, 2019
Perrigo Company plc (NYSE; TASE: PRGO) announced today that it has entered into a definitive agreement to acquire the branded OTC rights to Prevacid® from GlaxoSmithKline.
July 15, 2019
Perrigo Donates $50,000 to the Saugatuck Center for the Arts to Support an Entire Year of Arts Education Programming
DUBLIN, Ireland and Allegan, Michigan – July 15, 2019 --The Perrigo Company Charitable Foundation is proud to announce a donation of $50,000 to the Saugatuck Center for the Arts (SCA) which will support an entire year of arts education programming throughout the tri-county areas of Allegan, Kent, and Ottawa Counties.
July 08, 2019
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has completed the previously announced divestiture of its Animal Health business to PetIQ (NASDAQ: PETQ) for $185 million.
July 03, 2019
Perrigo Announces FDA Final Approval and Launch of the AB-Rated Generic Version of Metrogel-Vaginal® Gel
Perrigo Company plc (NYSE; TASE: PRGO) today announced its product development partner received final approval from the U.S. Food and Drug Administration for its AB-rated Abbreviated New Drug Application (“ANDA”) referencing Metrogel-Vaginal® (metronidazole vaginal gel 0.75%). Perrigo will acquire full ownership of the ANDA under a pre-existing arrangement with its partner within 30 days and anticipates launching this product immediately thereafter.
July 02, 2019
Perrigo Company plc (NYSE; TASE: PRGO) today announced the successful completion of its acquisition of Ranir Global Holdings LLC ("Ranir"), the leading global store brand supplier of oral self-care products, for $750 million in cash. This transaction advances Perrigo's transformation to a consumer-focused, self-care company while enhancing its position as a global leader in consumer self-care solutions.
July 01, 2019
Families in Allegan County who need home delivered meals will now have additional access thanks to the Perrigo Charitable Foundation’s $40,000 gift to West Michigan’s Meals on Wheels Program.
May 21, 2019
Dublin, Ireland – May 21, 2019 – Perrigo Company plc (NYSE; TASE: PRGO) today announced its partner received final approval from the U.S.